The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and ...

Verona Pharma has claimed FDA approval for its chronic obstructive pulmonary disease (COPD) drug ensifentrine ... given the somewhat tongue-twisting brand name of Ohtuvayre – is the first ...

The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...

A global elderly and aging population has significant impacts, not only in terms of individual health risk but in terms of ...

US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively ...

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

Verona Pharma has blockbuster hopes for its recently approved drug for chronic obstructive pulmonary disorder (COPD), and preliminary sales figures for the drug suggest it is heading in the right ...

Does gabapentinoid use increase the risk of severe exacerbation in patients with chronic obstructive pulmonary disease (COPD) ...

Gen Z is most likely to prefer brand-name drugs—despite being an average 79% more expensive than their generic counterparts—according to a Tebra survey published in January 2025.

Jazz Pharmaceuticals has drummed up a deal in double time, agreeing to buy Chimerix for $935 million just days after its CEO ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Inogen shows solid B2B growth, but guidance and margin issues hurt sentiment. Learn why INGN stock is a speculative play with ...